Related Experiment Video

Updated: Jan 31, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.8K

Drug discovery of anticancer drugs targeting methylenetetrahydrofolate dehydrogenase 2

Ayumu Asai1,2,3, Jun Koseki1, Masamitsu Konno2

  • 1Department of Medical Data Science, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.

Heliyon
|December 25, 2018
PubMed

Insights

Researchers identified Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) as a promising target for new anticancer drugs. This study confirms MTHFD2’s role in cancer and designs potential inhibitors to reduce drug side effects.

Area of Science:

  • Oncology
  • Drug Discovery
  • Biochemistry

Background:

  • Anticancer drugs often cause severe side effects by affecting healthy cells.
  • Targeting cancer-specific features is crucial for developing safer therapeutics.
  • Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is frequently overexpressed in various cancers.

Purpose of the Study:

  • To validate MTHFD2 as a viable drug discovery target for cancer treatment.
  • To design novel anticancer agents specifically inhibiting MTHFD2.
  • To explore the potential of MTHFD2 inhibitors in reducing chemotherapy-related adverse effects.

Main Methods:

  • Analysis of clinical data to assess MTHFD2 expression and its correlation with cancer prognosis.
  • In silico screening and drug design techniques to identify MTHFD2 inhibitors.
  • Biochemical assays to determine binding interactions and effects on MTHFD2 metabolites.

Main Results:

  • MTHFD2 is significantly enhanced in most cancer types compared to normal tissues.
  • MTHFD2 expression levels correlate with patient prognosis across various cancers.
  • In silico methods identified candidate MTHFD2 inhibitors with key binding interactions.
  • These inhibitors effectively reduced MTHFD2 metabolite levels in cancer cells.

Conclusions:

  • MTHFD2 is a validated and promising therapeutic target for anticancer drug development.
  • In silico drug design successfully identified potential MTHFD2 inhibitors.
  • Targeting MTHFD2 offers a strategy to develop anticancer drugs with minimized adverse effects on healthy tissues.
Keywords:
Cancer researchMolecular biologyPharmaceutical science

More Related Videos

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.2K
Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes11:31

Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes

Published on: February 18, 2020

8.3K

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.3K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.7K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
440
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
158
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268